

Improving the Response of Global Public Health in a Fast-changing World

Joint UNICEF, UNFPA and WHO meeting with manufacturers and suppliers of
in vitro diagnostic products, vaccines & immunization devices, finished pharmaceutical products, active
pharmaceutical ingredients, contraceptive devices and vector control products
2–5 December 2019, UN City, Copenhagen, Denmark

DAY 1	MONDAY, 2 DECEMBER
07:30–08:45 MEETING REGISTRATION: ENTRANCE TO UN CITY	
PLENARY: IMPROVING THE RESPONSE OF GLOBAL PUBLIC HEALTH IN A FAST-CHANGING WORLD	
08:45–08:50	Meeting opening and meeting overview <i>Joel Schaefer, Communication Officer, Office of WHO Director-General</i>
08:50–09:05	Welcome from meeting host agencies <i>Hanne Bak Pedersen (Deputy Director, Programme Supply & Market Influencing, UNICEF Supply Division), Eric Dupont (Chief, Procurement Services Branch, UNFPA) & Dr Mariângela Simão (Assistant Director-General, Access to Medicines and Health Products, WHO Headquarters)</i>
09:05–09:15	Administrative / security arrangements <i>Jesper Palm Lundorf, UN Office of the Designated Official for Security</i>
09:15–09:20	Overview of the day's themes and introduction to keynote address and response <i>Joel Schaefer, Communication Officer, Office of WHO Director-General</i>
09:20–09:40	Keynote address: "Fast Change, Slow Response" <i>Dr Soumya Swaminathan, Chief Scientist, WHO Headquarters</i>
09:40–10:00	Keynote address response: Using AI to Change the Game in Global Response <i>Dr Padmanabhan Anandan, CEO, Wadhvani Institute for Artificial Intelligence</i>
10:00–10:10	Quick questions <i>Moderated by Joel Schaefer, Communication Officer, Office of WHO Director-General</i>
10:10–10:40 Coffee / tea break	
Theme 1 Emergency Preparedness: Progress Made but Not There Yet	
10:40–10:45	Introduction to Theme 1 <i>Joel Schaefer, Communication Officer, Office of WHO Director-General</i>
10:45–11:05	Challenges in Emergency Preparedness <i>Dr Hilde de Clerck, Emerging Infections Advisor, Médecins Sans Frontières – Operational Centre, Brussels, Belgium</i>
11:05–11:25	Dx / Technology (title TBD) <i>Catharina Boehme, CEO, Foundation for Innovative New Diagnostics</i>
11:25–11:35	Quick questions <i>Moderated by Joel Schaefer, Communication Officer, Office of WHO Director-General</i>

Theme 2	Communication to Reduce Human “Resistance” to Care
11:35–11:40	Introduction to Theme 2 <i>Joel Schaefer, Communication Officer, Office of WHO Director-General</i>
11:40–12:00	Communication for Emergencies / Resistance (title TBD) <i>Cristiana Salvi, Programme Area Manager, WHO Health Emergencies Programme, WHO Regional Office for Europe</i>
12:00–12:20	Building resilient demand for vaccination <i>Katrine Bach Haabersaat, Technical Officer, Vaccine-preventable Diseases and Immunization, WHO Regional Office for Europe</i>
12:20–12:30	Quick questions <i>Moderated by Cristiana Salvi, Programme Area Manager, WHO Health Emergencies Programme, WHO Regional Office for Europe</i>
12:30–13:45	Sandwich lunch
Theme 3	Progress and Outlook for Global Health Initiatives
13:45–13:50	Introduction to Theme 3 <i>Joel Schaefer, Communication Officer, Office of WHO Director-General</i>
13:50–14:10	Access to Treatment for Childhood Cancer <i>Dr Scott Howard, WHO Consultant, Cancer Control, Department of Noncommunicable Diseases, WHO Headquarters, Professor, University of Health Science Center, Memphis, USA and Secretary General, International Pediatric Oncology Society</i>
14:10–14:30	Access to Diagnosis and Treatment for Hepatitis <i>Dr Nicole Seguy, Joint Tuberculosis, HIV/AIDS & Hepatitis Programme, WHO Regional Office for Europe</i>
14:30–14:50	Diagnosis and Treatment of Diabetes <i>Dr Hans Hogerzeil, Emeritus Professor, Groningen University</i>
14:50–15:10	Antimicrobial Resistance: towards Viable Markets for Diagnostics and Antibiotics <i>Daniel Berman, Lead, Global Health Team, Nesta Foundation</i>
15:10–15:20	Quick questions <i>Moderated by Joel Schaefer, Communication Officer, Office of WHO Director-General</i>
15:20–16:00	Coffee / tea break
Theme 4	Global Health Landscapes
16:00–16:05	Introduction to Theme 4 <i>Joel Schaefer, Communication Officer, Office of WHO Director-General</i>
16:05–16:25	WHO prequalification: “Preserve the Core, Stimulate Progress” <i>Deus Mubangizi, Coordinator, WHO Prequalification Team</i>
16:25–16:45	Regulation of Vector Control Products: What’s New? <i>Dr Angus Spiers, Director, Innovation to Impact</i>
16:45–17:05	Pharma Landscape: Challenges & Opportunities <i>Dr Julie Gerberding, Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy, and Population Health, Merck & Co., Inc.</i>
17:05–17:15	Quick questions <i>Moderated by Joel Schaefer, Communication Officer, Office of WHO Director-General</i>
17:15–17:30	Wrap-up <i>By Joel Schaefer, Communication Officer, Office of WHO Director-General</i>
17:30–19:00	Reception for all participants

DAY 2	TUESDAY, 3 DECEMBER
07:30–08:45	MEETING REGISTRATION: ENTRANCE TO UN CITY
<p>Day 2 will consist of a procurement track and five prequalification tracks, held in parallel. In addition, a session on “Local production and technical assistance” will be held from 15:30, i.e. in parallel with the latter part of the procurement track.</p> <p>Coffee/tea breaks: 11:00–11:30 & 15:30–16:00 & Lunch break: 13:00–14:00</p>	
PROCUREMENT: UPDATES & CHALLENGES	
08:45–09:00	<p>Introduction to procurement updates <i>Given by Francisco Blanco, Chief of Quality Assurance Centre, UNICEF Supply Division</i></p>
09:00–09:20	<p>UNICEF procurement process, volume/price updates <i>Cynthia Kamtengeni, Contracts Manager, Medicines and Nutrition Centre, UNICEF Supply Division & Robert Matthews, Contracts Manager, Health Technology Centre, UNICEF Supply Division</i></p>
09:20–09:30	<p>Q&A <i>Chaired by Francisco Blanco, Chief of Quality Assurance Centre, UNICEF Supply Division</i></p>
09:30–09:50	<p>UNFPA procurement process, volume/price updates <i>Roberto Mena, Procurement Specialist, Strategic Procurement, UNFPA</i></p>
09:50–10:00	<p>Q&A <i>Chaired by Francisco Blanco, Chief of Quality Assurance Centre, UNICEF Supply Division</i></p>
10:00–10:20	<p>Global Fund’s approach to procurement <i>Azikhon Jafarov, Manager, Global Sourcing Health Technologies</i></p>
10:20–10:30	<p>Q&A <i>Chaired by Francisco Blanco, Chief of Quality Assurance Centre, UNICEF Supply Division</i></p>
10:30–10:50	<p>PAHO Procurement & Health in the Americas <i>Daniel Rodriguez, Director, Procurement and Supply Management, Pan American Health Organization</i></p>
10:50–11:00	<p>Q&A <i>Chaired by Francisco Blanco, Chief of Quality Assurance Centre, UNICEF Supply Division</i></p>
11:00–11:30	Coffee/ tea break
11:30–11:40	<p>Introduction to procurement challenges <i>Given by Lisa Hedman, Technical Officer, Innovation, Access and Use, WHO Headquarters</i></p>
11:40–12:00	<p>Forecasting for decision-making <i>Vineet Prabhu, Associate Director, Market Intelligence, Clinton Health Access Initiative</i></p>
12:00–12:10	<p>Q&A <i>Chaired by Lisa Hedman, Technical Officer, Innovation, Access and Use, WHO Headquarters</i></p>
12:10–12:30	<p>Procurement for progressing global health initiatives: PAHO and HEARTS <i>Jordi Balleste, Jordi Balleste, Strategic Fund Unit Chief, Procurement and Supply Management, Pan American Health Organization</i></p>
12:30–12:50	<p>Biotherapeutics for cancer: ensuring quality, safety and efficacy <i>Dr Guido Pante, Expert, Biopharmaceutical Products, Medicines Assessment, WHO Prequalification Team</i></p>
12:50–13:00	<p>Combined Q&A for above two topics <i>Chaired by Daniel Rodriguez, Director, Procurement and Supply Management, Pan American Health Organization</i></p>
13:00–14:00	Lunch

14:00–14:05	Introduction <i>Lisa Hedman, Technical Officer, Innovation, Access and Use, WHO Headquarters</i>
14:05–14:30	Implications for manufacturers of updated WHO guidelines <i>Dr Sabine Kopp, Scientist, Technologies Standards and Norms, WHO Headquarters</i>
14:30–14:55	Country perspective on procurement of medicines: Iraq case study <i>Dr Fadia Hanna, Senior Chief Manager & Dr Ahmed Jabbar, Chief Pharmacist-Import Manager, Ministry of Health, Iraq and Amgad Gholam Abbas Gaafar, Logistician, WHO Country Office, Iraq</i>
14:55–15:20	Challenges of TB medicines market and sustainable pricing: getting the balance right <i>Dr Kaspars Lunte, Global Sourcing Officer, Stop TB & Dr Magali Babaley, Strategic Procurement and Business Intelligence Manager</i>
15:20–15:30	Combined Q&A for above three topics <i>Chaired by Lisa Hedman, Technical Officer, Innovation, Access and Use, WHO Headquarters</i>
15:30–16:00	Coffee/tea break
16:00–16:25	UNDP procurement processes, needs and challenges <i>Dr Cécile Macé, Senior Health Procurement and Supply Management Adviser, UNDP</i>
16:25–16:45	Procurement for treatment of neglected tropical diseases: what's new? <i>Hye Lynn Choi, Technical Officer, Prequalification Team/Department of Neglected Tropical Diseases, WHO Headquarters</i>
16:45–17:00	Combined Q&A for above two topics <i>Chaired by Lisa Hedman, Technical Officer, Innovation, Access and Use, WHO Headquarters</i>
WHO IN VITRO DIAGNOSTICS (IVDS) PREQUALIFICATION TRACK	
08:45–09:00	IVD prequalification for new applicants: an overview <i>Irena Prat, Group Lead, IVD Assessment, WHO Prequalification Team</i>
09:00–10:20	Introduction to IVD assessment <i>Helena Ardura-Garcia, Technical Officer & Charles Chiku, Technical Officer, IVD Assessment, WHO Prequalification Team</i>
10:20–10:40	Introduction to IVD inspection <i>Dr Joey Gouws, Group Lead, Inspection Services, WHO Prequalification Team</i>
10:40–11:00	Q&A <i>Chaired by Irena Prat, Group Lead, IVD Assessment, WHO Prequalification Team</i>
11:00–11:30	Coffee/ tea break
11:30–11:40	Introduction to IVD prequalification assessment update <i>Irena Prat, Group Lead, IVD Assessment, WHO Prequalification Team</i>
11:40–12:40	Dossier Assessment <i>Dr Mark Lanigan, Technical Officer, IVD Assessment, WHO Prequalification Team</i> Performance Evaluation <i>Dr Anne-Laure Page, Scientist, IVD Assessment, WHO Prequalification Team</i> Technical guidance and specifications <i>Dr Ute Ströher, Technical Officer, IVD Assessment, WHO Prequalification Team</i> Changes <i>Helena Ardura-Garcia, Technical Officer, IVD Assessment, WHO Prequalification Team</i>
12:40–13:00	Q&A <i>Chaired by Irena Prat, Group Lead, IVD Assessment, WHO Prequalification Team</i>
13:00–14:00	Lunch



14:00–14:45	IVD inspection update and Q&A <i>Stephanie Croft, Inspector, Inspection Services, WHO Prequalification Team</i>
14:45–15:15	Expert Review Panel for Diagnostics: update <i>Dr René Becker-Burgos, Quality Assurance Specialist for Diagnostics Products, Global Fund.</i>
WHO MEDICINES PREQUALIFICATION TRACK	
08:45–09:00	Introduction to medicines assessment update <i>Dr Matthias Stahl, Group Lead, Medicines Assessment, WHO Prequalification Team</i>
09:00–10:30	Quality <i>Dr Lynda Paleshnuik, Lead Quality Assessor, Medicines Assessment</i> Bioequivalence <i>Dr John Gordon, Lead Bioequivalence Assessor, Medicines Assessment, , WHO Prequalification Team, WHO Prequalification Team</i> Active pharmaceutical ingredients <i>Dr Antony Fake, API Assessment Focal Point, Medicines Assessment; WHO Prequalification Team</i> Update on WHO Public Assessment Reports <i>Dr Regine Lehnert, Clinical Assessor, Medicines Assessment, WHO Prequalification Team</i> Biosimilar products pilot <i>Dr Guido Pante, Expert, Biotherapeutic Products, Medicines Assessment, WHO Prequalification Team</i>
10:30–11:00	Q&A <i>Chaired by Dr Matthias Stahl, Group Lead, Medicines Assessment, WHO Prequalification Team</i>
11:00–11:30	Coffee/ tea break
11:30–12.30	Medicines inspection update and Q&A <i>Vimal Sachdeva, Inspector, Inspection Services, WHO Prequalification Team</i>
WHO VACCINES & IMMUNIZATION DEVICES PREQUALIFICATION TRACK	
08:45–09:20	WHO vaccines prequalification overview <i>Carmen Rodriguez-Hernandez, Group Lead, Vaccines Assessment, WHO Prequalification Team</i>
09:20–09:40	Vx inspection update <i>Mustapha Chafai, Inspector, Inspection Services, WHO Prequalification Team</i>
09:40–10.00	Q&A <i>Chaired by Carmen Rodriguez-Hernandez, Group Lead, Vaccines Assessment, WHO Prequalification Team</i>
10:00–10.45	Vaccine assessment: CMC (chemistry, manufacturing and control) and quality and clinical data <i>Oliver Lapujade, Scientist, Vaccines Assessment, WHO Prequalification Team</i>
10:45–11:00	Q&A <i>Chaired by Carmen Rodriguez-Hernandez, Group Lead, Vaccines Assessment, WHO Prequalification Team</i>
11:00–11.30	Coffee/ tea break
11:30–12.00	Vaccines testing: initial evaluation and post-prequalification monitoring <i>Dr Ute Roszkopf, Scientist, Regulatory Systems Strengthening Team</i>
12:00–12.15	Q&A <i>Chaired by Rolando Dominguez Morales, Scientist, Vaccines Assessment, WHO Prequalification Team</i>

12:15–12.45	Post-prequalification <i>Rolando Dominguez Morales, Scientist, Vaccines Assessment, WHO Prequalification Team</i>
12:45–13.00	Q&A <i>Chaired by Oliver Lapujade, Scientist, Vaccines Assessment, WHO Prequalification Team</i>
13:00–14.00	Lunch
14:00–14:30	Regulatory challenges of prequalified vaccines supplied through the UN system <i>Olivier Lapujade, Scientist, Vaccines Assessment, WHO Prequalification Team</i>
14:30–14:45	Q&A <i>Chaired by Carmen Rodriguez-Hernandez, Group Lead, Vaccines Assessment, WHO Prequalification Team</i>
14:45–15.15	Prequalification of immunization equipment: implications for vaccines <i>Dr Isaac Gobina, Technical Officer, Immunization Devices Prequalification</i>
15:15–15.30	Q&A <i>Chaired by Carmen Rodriguez-Hernandez, Group Lead, Vaccines Assessment, WHO Prequalification Team</i>
WHO VECTOR CONTROL PRODUCT PREQUALIFICATION TRACK	
08:45–09:00	Introduction to vector control assessment update & developments <i>Marion Law, Group, Vector Control, Vaccines Assessment, WHO Prequalification Team</i>
09:00–11:00	Dossier components & timelines & challenges for manufacturers (& how to overcome them) <i>Dominic Schuler, Technical Officer, Vector Control, Vaccines Assessment, WHO Prequalification Team</i> Data requirements (efficacy) <i>Dr Jeanette Martinez, Technical Officer, Vector Control, Vaccines Assessment, WHO Prequalification Team</i> Joint Meeting on Pesticide Requirements: update on outcomes for 2018 & 2019 & joint meeting & workplan for 2020 <i>Marion Law, Group Lead, Vector Control, Vaccines Assessment, WHO Prequalification Team</i>
11:00–11.30	Coffee/ tea break
11:30–12.00	Vector control inspection update <i>Dr Joey Gouws, Group Lead, Inspection Services, WHO Prequalification Team</i>
12:00–13.00	Q&A <i>Chaired by Marion Law, Group Lead, Vector Control, Vaccines Assessment, WHO Prequalification Team</i>



UNFPA PREQUALIFICATION OF CONTRACEPTIVE DEVICES & MARKETS TRACK	
08:50–09:05	UNFPA prequalification programme update <i>Ashley Moyo, Technical Analyst, UNFPA Procurement Services Branch</i>
09:05–09:40	Reporting changes to the prequalified product/site <i>Dr Siva Kumar, Technical Expert Consultant, UNFPA</i>
09:40–10:00	Quality complaints <i>Dr William Potter, Technical Expert Consultant, UNFPA</i>
10:00–10:30	Post-market surveillance <i>David Hill, Technical Expert Consultant, UNFPA</i>
10:30–11:00	Condom storage conditions and conducting stability studies <i>Dr Siva Kumar, Technical Expert Consultant, UNFP</i>
11:00–11.30	Coffee/ tea break
11:30–11.45	Condom storage conditions and conducting stability studies (continued) <i>Dr Siva Kumar, Technical Expert Consultant, UNFPA</i>
11:45–12.30	Quality monitoring strategies <i>Dr William Potter, Technical Expert Consultant, UNFPA</i>
12:30–13.00	Fee structure <i>Ashley Moyo, Technical Analyst, UNFPA Procurement Services Branch</i>
13:00–14.00	Lunch
15:30–16.00	Breakout session: Viable commercial markets for reproductive health products markets: are they possible without donors? <i>Led by Ben Light, Senior Policy Adviser, Family Planning & Reproductive Health Supplies Coalition, UNFPA</i>
LOCAL PRODUCTION & TECHNICAL ASSISTANCE	
15:30–15:40	Introduction TBD
15:40–16.00	Leveraging and cultivating enabling factors for local production <i>Dr Ji Cui Dong, Programme Manager, Local Production, Regulatory Systems & Strengthening Team, WHO Headquarters</i>
16:00–16.15	Q&A <i>Chaired by TBD</i>
16:15–17:05	Technical assistance for IVD manufacturers <i>Dr Gaby Vercauteren, Senior Advisor, Regulatory Systems Strengthening, WHO Headquarters</i>
17:05–17:25	Technical assistance for medicines manufacturers <i>Rutendo Kuwana, Technical Officer, Regulatory Systems Strengthening, WHO Headquarters</i>
17:25–17:45	Q&A <i>Chaired by TBD</i>



DAY 3	WEDNESDAY, 4 DECEMBER
07:30–08:30	MEETING REGISTRATION: ENTRANCE TO UN CITY
Day 3 will be held in plenary, with the exception of two lunchtime breakout sessions.	
WHO POLICY, DIAGNOSIS AND TREATMENT GUIDELINES UPDATES, AND WHO AND MODEL LIST UPDATES	
08:30-08:35	Introduction <i>Given by Deus Mubangizi, Coordinator, WHO Prequalification Team</i>
08:35-08:55	TB diagnostic policies and treatment guidelines updates <i>Dr Kerri Viney, Scientist, Laboratories, Diagnostics and Drug-Resistance, WHO Global TB Programme</i>
08:55-09:15	HIV and STI treatment guidelines updates <i>Dr Marco Vitoria, Medical Officer, Treatment and Care, Department of HIV/AIDS, WHO Headquarters</i>
09:15-09:35	Hepatitis B and C treatment guidelines updates <i>Dr Antons Mozalevskis, Medical Officer, HIV/AIDS & Hepatitis Programme, WHO Regional Office for Europe</i>
09:35-09:55	Malaria treatment guidelines update <i>Dr Peter Olumese, Medical Officer, Prevention, Diagnosis & Treatment, WHO Global Malaria Programme</i> Q&A <i>Chaired by Deus Mubangizi, Coordinator, WHO Prequalification Team</i>
09:55-10:15	Q&A <i>Chaired by Deus Mubangizi, Coordinator, WHO Prequalification Team</i>
WHO MODEL LIST UPDATES	
10:15–10:20	Introduction <i>Given by Deus Mubangizi, Coordinator, WHO Prequalification Team</i>
10:20–10:40	The 2nd WHO Model List of Essential In Vitro Diagnostics <i>Adriana Velazquez Berumen, Senior Advisor, Innovation, Access and Rational Use Team, WHO Headquarters</i>
10:40–11:00	The 21st WHO Model List of Essential Medicines <i>Bernadette Cappello, Technical Officer, Secretariat, Essential Medicines List, WHO Headquarters</i> Q&A <i>Chaired by Deus Mubangizi, Coordinator, WHO Prequalification Team</i>
11:00–11:30	Coffee/tea break



REGULATORY OVERSIGHT IN THE LIFECYCLE OF A MEDICAL PRODUCT	
11:30–11:35	Introduction <i>Given by Emer Cooke, Director, Director, Department of Regulation of Medicines and other Health Technologies, WHO Headquarters</i>
Evolving Regulatory Concepts	
11:35–11:55	Good regulatory and good reliance practices <i>Dr Samvel Azatyan, Group Lead, Regulatory Networks and Harmonization, Regulatory Systems Strengthening, WHO Headquarters</i>
11:55–12:15	The WHO Global Benchmarking Tool (GBT) <i>Dr Ali Khadem Broojerdi, Scientist, Regulatory Systems Strengthening, WHO Headquarters</i>
12:15–12:35	WHO Listed Authorities: from concept to practice <i>Mr Hiiti Sillo, Scientist, Regulatory Systems Strengthening, WHO Headquarters</i>
12:35–13:00	Q&A <i>Chaired by Dr Ali Khadem Broojerdi, Scientist, Regulatory Systems Strengthening, WHO Headquarters</i>
13:00–14:00	Lunch
LUNCHTIME BREAKOUT SESSIONS	
12:45–14:15	Breakout session: Safe abortion <i>Led by Sophia Ahsan, Market Development Officer, Deputy Director, Reproductive Health Supplies Coalition, with the participation of TBD UNFPA and WHO Headquarters</i> <i>Lunch will be available outside the meeting room for those participating</i>
12:45–14:15	Breakout session: The benefits of The International Pharmacopoeia for manufacturers <i>Led by Dr Herbert Schmidt, Technical Officer, Technical Standards and Norms Team, WHO Headquarters, with the participation of TBD</i> <i>Lunch will be available outside the meeting room for those participating</i>
Registration and Marketing Authorization	
14:00–14:15	Collaborative procedures: A brief introduction <i>Dr Samvel Azatyan, Group Lead, Regulatory Networks and Harmonization, Regulatory Systems Strengthening, WHO Headquarters</i>
14:15–15:00	Collaborative procedures: Best practices and remaining hurdles Moderated panel discussion (including Q&A) <i>Regulators from Thailand, Zambia and Ukraine, and representatives of the European Medicines Agency (EMA) (Dr Agnès Saint-Raymond), the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) (Stephanie McGauley, Pfizer Global Brands (UK), International Generic and Biosimilar medicines Association (Imtiyaz Basade, Mylan Laboratories, India) and WHO (Dr Samvel Azatyan)</i> <i>Moderated by: Dr Petra Doerr, Petra Doerr Consulting Ltd.</i>
15:00–15:30	Coffee/tea break



Market Surveillance	
15:30–15:35	Introduction <i>TBD, Uppsala Monitoring Centre</i>
15:35–16:00	Pharmacovigilance systems and procedures: the manufacturer’s role and responsibilities <i>Dr Shanthy Pal, Group Lead: Medicines Safety and Vigilance, WHO Headquarters</i>
16:00–16:20	Where are we in the fight against substandard and falsified medical products? <i>Pernette Bourdillon Esteve, Analyst, Safety and Vigilance Team, WHO Headquarters</i>
16:20–16:30	Q&A <i>Chaired by TBD, Uppsala Monitoring Centre</i>
16:30–17:30	The “sartan case”: lessons learnt for regulators and manufacturers Brief introduction (what has happened and why) <i>Dr Susanne Keitel, Director, European Directorate for the Quality of Medicines (EDQM)</i> Moderated panel discussion <i>With the participation of: EDQM (Dr Susanne Keitel); the European Heart Network (Marilena Vrana), EMA (Dr Agnès Saint-Raymond); IFPMA (Sylvia Meillerai, MSD Europe); Medicines for Europe (TBD, TEVA Europe) and WHO (Dr Sabine Kopp).</i> <i>Moderated by: Dr Petra Doerr, Petra Doerr Consulting Ltd.</i>
OFFICIAL MEETING CLOSURE	
17:30–17:45	Meeting highlights and recommendations TBD
DAY 4	THURSDAY, 5 DECEMBER
1-TO-1 MEETINGS WITH HOST AND PARTICIPATING AGENCIES	
Entrance to UN City for a 1-to-1 meeting will be dependent on meeting confirmation (including meeting time and location) from the agency with whom the meeting has been requested.	
Meeting participants can request a meeting by contacting these agency staff:	
<ul style="list-style-type: none"> • for Pan American Health Organization contact Martha Suazo (suazomar@paho.org) • for Global Drug Facility contact Kaspars Lunte (kasparsl@stoptb.org) • for Global Fund contact Amelie Darmon (amelie.darmon@theglobalfund.org) for pharmaceuticals and René Becker-Burgos (rene.becker-burgos@theglobalfund.org) for diagnostic products • for UNDP contact Zafar Yuldashev (zafar.yuldashev@undp.org) • for UNFPA contact both Minna Soikkeli (soikkeli@unfpa.org) and Ashley Moyo (asmoyo@unfpa.org) • for UNICEF contact Charlotte Armand Nielsen (carnielsen@unicef.org) • for WHO procurement contact Sophie Laroche (laroches@who.int) or, for medicines for neglected tropical diseases specifically, Hye Lynn Choi (hchoi@who.int). • Charles Chiku — for in vitro diagnostics assessment/inspection/performance evaluation for WHO prequalification — chikuc@who.int • Matthias Stahl — stahlm@who.int — for medicines assessment for WHO prequalification • Vimal Sachdeva — sachdevav@who.int — for medicines inspection for WHO prequalification • Carmen Rodriguez-Hernandez — rodriguezhernandezc@who.int — for vaccines assessment or inspection for WHO prequalification • Seloi Mogatle — mogatle@unfpa.org — for assessment or inspection of contraceptive devices for WHO/UNFPA prequalification • Dominic Schuler — schulerd@who.int — for vector control product assessment or inspection for WHO prequalification • Gaby Vercauteren — vercautereng@who.int — for technical assistance for IVD manufacturers 	

- Rutendo Kuwana — kuwanaru@who.int — for **technical assistance for medicines manufacturers**
- Luther Gwaza — gwazal@who.int — for **collaborative registration**.